UNSPSC 51343306: Opaviraline

This classification denotes a reverse transcriptase inhibitor with the molecular formula C14H17FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q3A8EU2NMU, chemically known as 1(2h)-quinoxalinecarboxylic acid, 2-ethyl-7-fluoro-3,4-dihydro-3-oxo-, 1-methylethyl ester, (2s)- but generally known as opaviraline, which bears US NIH Compound Identifier 154048. The term OPAVIRALINE is an International Non-Proprietary Name. Most nations schedule opaviraline under HS 29339990 and SITC 51577.

As of Q4 2014, OPAVIRALINE remains the US FDA Preferred Term for this commodity. Opaviraline bears US NLM identifiers UMLS ID C0910816 and NCI Concept Code C90786. SMILES: CCC1C(=O)NC2=C(N1C(=O)OC(C)C)C=C(C=C2)F.

UNSPSC 51343306 Opaviraline, a Commodity code, captures state and local procurement of pharmaceutical products and related health-care supplies, though recent opportunities under this code show a scattered portfolio spanning naloxone and drug deactivation systems, first-aid medical supplies, and generic multi-source pharmaceuticals distributed through state cooperative purchasing vehicles. State and local issuing bodies range from county health departments and city fire departments to state health agencies and multi-state cooperative purchasing alliances. Seminole County, Florida (IFB 60459723LAS) solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive sealed bidding, while the City of Tampa (26P00145) sought 169 line items of medical and first-aid supplies for its Fire Department Rescue Division through an ITB with a $700,000 estimated contract value and a sheltered-market set-aside for certified Small Local Business Enterprises. The Texas Health and Human Services Commission issued a Request for Information to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements, signaling state interest in alternative pharmacy supply channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered an RFP for generic multi-source pharmaceuticals and OTC products distributed via three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with a March 26, 2026 response deadline and July 1, 2026 contract effective date.

Recent activity clusters in Florida, Texas, and Minnesota, with the MMCAP vehicle serving multiple state and local jurisdictions including Oregon. The Seminole County and Tampa Fire Department procurements represent direct county and municipal health-and-safety supply chains, while the Texas HHS and MMCAP opportunities reflect state-level or multi-state cooperative aggregate purchasing for pharmacy networks. Vendors responding to this code face varying compliance requirements—E-Verify, drug-free workplace certifications, insurance minimums ranging from $2 million to $5 million per occurrence, FDA compliance, cGMP certification, and DSCSA supply-chain security standards. Award mechanisms include fixed-fee unit pricing (Seminole County), lowest-responsive-responsible bidding with renewal options (Tampa), and price-competitiveness evaluation weighted at 75 percent within administrative and technical gates (MMCAP). The code shows modest recent activity concentrated in health-department and fire-rescue supply replenishment and state-level pharmaceutical contracting, rather than high-volume commodity distribution.